(Q49906338)

23 February 2018

title

Infections in Patients Receiving Multiple Sclerosis Disease-Modifying Therapies. (English)

1 reference

23 February 2018

0 references

Elena Grebenciucova

1

1 reference

23 February 2018

Amy Pruitt

series ordinal

2

1 reference

23 February 2018

publication date

22 September 2017

1 reference

23 February 2018

Current Neurology and Neuroscience Reports

published in

1 reference

23 February 2018

volume

17

1 reference

23 February 2018

issue

11

1 reference

23 February 2018

page(s)

88

1 reference

23 February 2018

https://scigraph.springernature.com/pub.10.1007/s11910-017-0800-8

exact match

0 references

cites work

Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Glatiramer acetate improves regulatory T-cell function by expansion of naive CD4(+)CD25(+)FOXP3(+)CD31(+) T-cells in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-cells in the CNS of mice with relapsing-remitting or chronic EAE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Biological activity of glatiramer acetate on Treg and anti-inflammatory monocytes persists for more than 10years in responder multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Interferons and their actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Type I interferons in infectious disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Abnormal levels of interferon-gamma receptors in active multiple sclerosis are normalized by IFN-beta therapy: implications for control of apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

The mechanism of action of interferon-β in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Interferon-beta modifies the peripheral blood cell cytokine secretion in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Haematological effects of interferon-beta-1a (Rebif) therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Pathophysiology of multiple sclerosis and the place of teriflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Effect of teriflunomide on QuantiFERON-TB Gold results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Effects of dimethyl fumarate on neuroprotection and immunomodulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Dimethylfumarate is a potent inducer of apoptosis in human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: Patient management considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

VCAM-1 expression in adult hematopoietic and nonhematopoietic cells is controlled by tissue-inductive signals and reflects their developmental origin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Fingolimod and risk of varicella-zoster virus infection: back to the future with an old infection and a new drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

VZV encephalitis that developed in an immunized patient during fingolimod therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Primary Cutaneous Histoplasma capsulatum Infection in a Patient Treated With Fingolimod: A Case Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: A case report and review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Immunosenescence: the Role of Aging in the Predisposition to Neuro-Infectious Complications Arising from the Treatment of Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

The pathophysiologic role of alpha 4 integrins in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Varicella zoster-associated retinal and central nervous system vasculitis in a patient with multiple sclerosis treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Varicella-zoster virus acute myelitis in a patient with MS treated with natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Extratemporal herpes encephalitis during natalizumab treatment: A case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

The effect of plasma exchange on serum anti-JC virus antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Natalizumab-associated PML: Challenges with incidence, resulting risk, and risk stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Influenza vaccination increases anti-JC virus antibody levels during treatment with Natalizumab: Case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus: a systematic literature review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Acute and chronic B cell depletion disrupts CD4+ and CD8+ T cell homeostasis and expansion during acute viral infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Progressive multifocal leukoencephalopathy after natalizumab discontinuation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Anti-JC virus antibodies in rituximab-treated patients with neuromyelitis optica spectrum disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Visceral disseminated varicella zoster virus infection after rituximab treatment for granulomatosis with polyangiitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukaemia treated with alemtuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

IFN-β induces the proliferation of CD4+CD25+Foxp3+ regulatory T cells through upregulation of GITRL on dendritic cells in the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0800-8

Dimethylfumarate reduces leukocyte rolling in vivo through modulation of adhesion molecule expression

21 January 2018

1 reference

12 December 2020

Mechanisms of the antiviral action of interferons

1 reference

12 December 2020

Monoclonal antibodies and progressive multifocal leukoencephalopathy.

1 reference

12 December 2020

Contrasting effects of alpha, beta, and gamma interferons on nonspecific suppressor function in multiple sclerosis

1 reference

12 December 2020

Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level

1 reference

12 December 2020

PML in a patient with lymphocytopenia treated with dimethyl fumarate

1 reference

12 December 2020

Fumarates Promote Cytoprotection of Central Nervous System Cells against Oxidative Stress via the Nuclear Factor (Erythroid-Derived 2)-Like 2 Pathway

1 reference

12 December 2020

PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter?

1 reference

12 December 2020

A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients

1 reference

12 December 2020

PML in a patient without severe lymphocytopenia receiving dimethyl fumarate

1 reference

12 December 2020

The effect of dimethyl fumarate (Tecfidera™) on lymphocyte counts: A potential contributor to progressive multifocal leukoencephalopathy risk

1 reference

12 December 2020

Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis

1 reference

12 December 2020

10.1007/S11910-017-0800-8

Identifiers

DOI

1 reference

23 February 2018

Dimensions Publication ID

0 references

1 reference

23 February 2018